Collaboration Agreement - License Agreement - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract revenue-related party									$ 23,372	$ 33,038
Deferred revenue	$ 5,000								5,000
Milestone payment will be recognized as revenue upon receiving the first regulatory approval	5,000								5,000
Fully utilized reimbursable research and development expenses	65,000								65,000
Research and development	8,281	$ 8,880	$ 9,754	$ 8,361	$ 7,673	$ 6,047	$ 11,656	$ 5,796	35,276	31,172
General and administrative	1,093	$ 1,320	$ 1,339	$ 1,542	1,201	$ 1,443	$ 1,931	$ 1,651	5,294	6,226
License Agreement with Grifols [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reimbursable research and development expenses by partner									65,000
Payments for development milestones by partner									$ 25,000
Patent coverage or orphan drug designation period									10 years
Percentage of reduction on royalty payment									50.00%
Fully burdened development expenses	$ 0				$ 8,100				$ 23,400	33,000
Research and development									22,200	30,200
General and administrative									1,200	2,400
Development costs for equipment and inventory										$ 400
Decrease in research and development expenses									8,000
Decrease in general and administrative expenses									$ 1,200
License Agreement with Grifols [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payments on net sales rate									12.50%
License Agreement with Grifols [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payments on net sales rate									20.00%